Tocilizumab (Actemra - Hoffmann-La Roche Limited) new indication: polyarticular juvenile idiopathic arthritis
CADTH
Record ID 32014000745
English
Authors' recommendations:
Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that tocilizumab be listed for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) if the following clinical criterion and condition are met:
1. Clinical Criterion: Inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). 2. Condition: Treatment should be initiated by a rheumatologist.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/cdr_complete_Actemra_Mar_24_14_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal, Humanized
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.